10:56 AM EDT, 07/01/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) has agreed to pay 10 million shekels ($2.7 million) to settle a potential anti-competition case related to its blood cancer treatment Imnovid, the Israel Competition Authority said Monday.

The agency said there were indications of the company's complicity in setting "unreasonable conditions" for the supply of Imnovid samples to a company that had wanted to conduct a trial with the aim of registering a generic version of the drug.

"The delay in supply, which lasted for about five months, could have delayed the entry of the competing generic drug into the market, and even resulted in generic competitors not entering the market, who might have been threatened from competing in the market as a result of the strict conditions placed on the supply of the drug," the agency said.

Bristol-Myers Squibb ( BMY ) agreed to pay 10 million shekels to Israel's state treasury without admitting to violating the Economic Competition Law, according to the agency.

The company didn't immediately respond to a request for comment from MT Newswires.

Price: 41.80, Change: +0.27, Percent Change: +0.64